Joann Jackson
Family · Pittsburgh, PANPI 1891218152
Payments from drug & device makers
Across 124 payments — averaging $20.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$1K
- AbbVie$449
- Gilead$300
- Janssen Products, LP$89
- Antares Pharma, Inc.$76
- Merck$64
- plus $304 from 12 others
What the payments were for
- Food & beverage$2,35394%
- Education$1536%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 60 | $1,225 |
| AbbVie | 21 | $449 |
| Gilead | 20 | $300 |
| Janssen Products, LP | 1 | $89 |
| Antares Pharma, Inc. | 4 | $76 |
| Merck | 3 | $64 |
| Johnson & Johnson(2 entities) | 2 | $51 |
| Otsuka America Pharmaceutical, Inc. | 2 | $50 |
| Theratechnologies Inc. | 2 | $36 |
| Halozyme Inc | 1 | $24 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $21 |
| Lundbeck LLC | 1 | $20 |
| Virtus Pharmaceuticals LLC | 1 | $18 |
| Indivior Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Dynavax Technologies Corporation | 1 | $17 |
| Abbott | 1 | $16 |
| Hologic Sales And Service, LLC | 1 | $16 |
How this compares
$2,507 in reported general payments places this provider in the 85th percentile of 4,717 family providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| DescovyEmtricitabine/Tenofov Alafenam | 76 | $158,168 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 29 | $98,725 |
| TivicayDolutegravir Sodium | 44 | $91,931 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 23 | $83,908 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 16 | $58,467 |
| ApretudeCabotegravir | 15 | $56,488 |
| OzempicSemaglutide | 28 | $26,373 |
| JardianceEmpagliflozin | 19 | $11,420 |
| EliquisApixaban | 16 | $8,593 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $7,356 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 19 | $4,329 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 23 | $878 |
| Ventolin HfaAlbuterol Sulfate | 11 | $552 |
| Atorvastatin Calcium | 76 | $384 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 11 | $375 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadDescovy, Biktarvy, Genvoya | $300 | $300,543115 claims |
| Viiv Healthcare CompanyTriumeq, Tivicay, Apretude | $1,225 | $247,14488 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,717 family providers in Pennsylvania.
Other family in Pittsburgh
- Kathleen ScholzPittsburgh$397K
- Kweilynn GreenePittsburgh$139K
- Jessica LindenbergerPittsburgh$131K
- Margaret RosenzweigPittsburgh$89K
- Patricia HabdasPittsburgh$83K
- Morgan ColePittsburgh$41K
- Amber GrinnellPittsburgh$33K
- Matthew BarnesPittsburgh$25K
- Alexander TatangeloPittsburgh$20K
- Sydney MurrayPittsburgh$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.